Navigation Links
Spring Bioscience launches highly sensitive PD-L1 (SP142) antibody, a component of Roche's immunotherapy assay
Date:8/25/2014

PLEASANTON, Calif., Aug. 25, 2014 /PRNewswire/ -- Spring Bioscience (Spring), a member of the Roche Group, today announced the launch of its PD-L1 (SP142) rabbit monoclonal immunohistochemistry (IHC) antibody1. This new PD-L1 clone was developed for Roche/Genentech's anti-PD-L1 (MPDL3280A) immunotherapy development program. The SP142 antibody is a component of the clinical trial assay designed by Ventana Medical Systems, Inc. (Ventana), and used in early and late stage clinical trials for various tumor types including non-small cell lung cancer (NSCLC) and urothelial bladder cancer (UBC).

As pharmaceutical companies continue to research and develop cancer drugs that target the immune system, measuring the amount of PD-L1 protein expressed on tumor cells and tumor-infiltrating immune cells may help assess the efficacy and durability of investigational drugs that inhibit the binding of the PD-L1 protein.

Internal comparison studies performed at Spring demonstrated that the PD-L1 (SP142) antibody outperformed other commercially available PD-L1 antibodies. "As with all IHC antibodies developed by Spring, the SP142 antibody will deliver the high quality and accuracy that clinical researchers need to confidently assess PD-L1 status in tissue samples," said Michael Rivers, GM, Spring Biosience. 

"The development of the PD-L1 (SP142) antibody, with its high degree of sensitivity and specificity, may make this a key component of a future companion diagnostic IHC test for Roche's investigational anti-PD-L1 therapy. As researchers strive to understand the clinical relevance of PD-L1 expression, this clone may offer a superior ability to stain and analyze both tumor and immune cells," said Doug Ward, VP and Lifecycle Leader, Ventana Compaion Diagnostics. "Ventana and Spring are committed to delivering gold standard biomarker detection solutions for companion diagnostic tests."

Spring Bioscience is known across the research industry for its quality development practices and for delivering a consistent supply of highly-specific antibodies. SP142 meets the company's high standards as a valuable tool for assessing PD-L1 expression in many different tumor types.

Recommended staining protocols are available for manual, semi-automated and VENTANA Discovery platforms for decreased assay development times.

To order or request additional information on SP142, please visit springbio.com or call (800) 787-6896 or (925) 474-8440. Orders can also be submitted via e-mail at spring.orders@ventana.roche.com with technical detail available through spring.tech@ventana.roche.com.

1PD-L1 (SP142) Rabbit Monoclonal Antibody is for Research Use Only (RUO). Not for use in diagnostic procedures.

About Spring Bioscience
Spring Bioscience, Inc. (Spring) is a leading developer of rabbit monoclonal antibodies, engineered for immunohistochemistry (IHC) and other applications in tissue-based cancer research. Founded by scientists with a primary focus on IHC, Spring has developed a proprietary menu of highly-sensitive antibodies (SP clones) that yield superior specificity and consistency in research and clinical practice. Spring is committed to high-quality development standards and also offers a portfolio of advanced detection and other complementary products for reliable, reproducible assessments of protein expression. Spring Bioscience was acquired by Ventana Medical Systems, Inc., a member of the Roche Group, in 2007. As an antibody center of excellence for Roche with strong pharmaceutical partnerships across the industry, Spring is at the frontier of antibody development for companion diagnostics, IVD and early clinical markers. Learn more at Springbio.com.

About Ventana Medical Systems, Inc.
Ventana Medical Systems, Inc. ("VMSI") (SIX: RO, ROG; OTCQX: RHHBY), a member of the Roche Group, innovates and manufactures instruments and reagents that automate tissue processing and slide staining for cancer diagnostics. VENTANA products are used in clinical histology and drug development research laboratories worldwide. The company's intuitive, integrated staining, workflow management platforms, and digital pathology solutions optimize laboratory efficiencies to help reduce errors, support diagnosis and enable informed treatment decisions by anatomic pathology professionals. Together with Roche, VMSI is driving Personalized Healthcare through accelerated drug discovery and the development of "companion diagnostics" to identify the patients most likely to respond favorably to specific therapies.

VENTANA, the VENTANA logo, and DISCOVERY are trademarks of Roche.

VMSI Media Relations
Jacqueline Bucher
Senior Director, Corporate Communications
Ventana Medical Systems, Inc.
Tel 520.877.7288 o
Tel 520.468.9145 m
e-mail: Jacquie Bucher

Photo - http://photos.prnewswire.com/prnh/20140822/139008


'/>"/>
SOURCE Spring Bioscience
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardium Exhibiting Its New FDA-Cleared Excellagen® At The 2012 Spring Symposium Of Advanced Wound Care
2. Top buyers including Atico, Coles Group Asia, Kmart, Staples, Office Depot and Target Australia pre-registered to attend Global Sources spring China Sourcing Fairs
3. Neusoft Medical Launches NeuViz 64 Multi-slice CT Scanner at CMEF Spring 2012
4. Islet Sciences Announces Strategic Alliance with Spring Point Project
5. Spring Bank Pharmaceuticals Closes $10.5 million Series A Financing to fund Phase I Clinical Trials in HCV-infected Patients
6. SI-BONE, Inc. Announces Spring Society Meeting Attendance
7. Pressure BioSciences, Inc. to Present at the SeeThruEquity Spring Investor Microcap Forum
8. GlySure CEO to Present ICU Trial Results at Spring Medtech Industry Conferences
9. Spring Allergies Start Strong and Last Long As Extreme Weather Patterns Continue
10. Hurel Receives $9.2 Million Series A Funding From Spring Mountain Capital
11. Neusoft Medical Launches New Products to Global Market at 2013 Spring CMEF
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... 27, 2017  Commended for their devotion to personalized service, ... as number one in the South Florida Business Journal,s 50 ... 5000 yearly list, the national specialty pharmacy has found its ... will soon be honored by SFBJ as the 2017 ... Set to receive his award in October, Bardisa said ...
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
(Date:9/22/2017)... 2017 AVACEN Medical (AVACEN) announced that its ... helping those with the widespread pain associated with fibromyalgia ... in Essex, England commented, "I ... experiencing no sleep at all, tremendous pain, with every ... recommend [the AVACEN 100] enough, how this has and ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... , ... Lori R. Somekh, founder of the Law Office of Somekh ... law and special needs planning attorneys. “Membership in ElderCounsel helps our office remain up ... network with elder law attorneys nationwide,” said Somekh. , ElderCounsel was ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Ellevate Network, ... in business to advocate for action towards gender equality at their inaugural Summit in ... around the globe, and reached a social audience of over 3 million. To watch ...
(Date:10/13/2017)... ... 2017 , ... Coveros, a leader in agile coaching services ... by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile Transformation ... Agile methodologies in a consistent and high value manner across CMS programs. Coveros ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics ... PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... of Morris F. Collen, a pioneer in the field of medical informatics, this prestigious ...
Breaking Medicine News(10 mins):